GEOGRAPHIC ATROPHY

This study tests a single injection into the eye of a new drug (SAR446597) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. About 104 participants aged 60 and older will be followed for 2 years, with an optional 3-ye…

This study tests whether transplanting lab-grown eye cells can help treat geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. About 20 people aged 55 and older will receive a transplant of their own stem-cell-derived retinal cells in…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier trials for geographic atrophy, a form of advanced age-related macular degeneration. The goal is to check long-term safety by monitoring eye health and side effects over time. Abou…

This study tests a new treatment called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 60 participants will receive a single injection of OpRegen cells under the retina during eye surgery. The go…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive injections into the eye, either with the new drug or an approved t…

This study tests the safety of a monthly eye injection called ASP3021 in 20 Japanese adults aged 40 and older who have geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. Participants receive injections into the affected eye for 12 mo…

This study tests a new drug called VOY-101 in 60 people aged 60 and older with advanced dry age-related macular degeneration (AMD), a condition that causes blind spots. The goal is to see if VOY-101 can slow the growth of these spots and preserve vision. The study starts with sma…

This study tests whether dapagliflozin, a drug used for diabetes, can slow the progression of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 70 adults aged 50 and older with non-foveal geographic atrophy will take the dr…

This study tests an experimental implant (CPCB-RPE1) placed under the retina to treat advanced dry age-related macular degeneration with geographic atrophy. About 24 people aged 55-90 will take part, with most receiving the implant and a few receiving a sham procedure. The goal i…

This study tests two imaging methods—central microperimetry and radial OCT—to see if they can more accurately measure the progression of geographic atrophy, a form of age-related macular degeneration that can lead to vision loss. Researchers will follow 80 participants aged 55 an…

This study uses a special camera to take extremely detailed pictures of the retina (the back of the eye) in both healthy people and those with eye diseases like Stargardt's or age-related macular degeneration. The goal is to see individual cells and blood vessels to better unders…

This study follows 1,000 people with geographic atrophy (an advanced form of age-related macular degeneration) who are already starting treatment with the drug Izervay. Researchers will collect information from medical records and surveys over up to 5 years to see how the drug is…